Results 101 to 110 of about 17,282 (226)

Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia. [PDF]

, 2005
It was recently reported that gene therapy using hepatocyte growth factor (HGF) has the potential to preserve cardiac function after myocardial ischemia. We speculated that this HGF gene therapy could also prevent ventricular arrhythmia.
Aoki, Motokuni, Hashimoto, Katsushi, Kaneda, Yasufumi, Kusano, Kengo Fukushima, Morishita, Ryuichi, Nakamura, Kazufumi, Ohe, Tohru, Yumoto, Akihisa   +7 more
core   +1 more source

Efficacy and Safety of Dronedarone in Overweight and Obesity: Post Hoc Analysis of the ATHENA Trial

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Introduction Obesity represents a prevalent condition with multiple comorbidities, including atrial fibrillation (AF). Dronedarone, an antiarrhythmic drug (AAD), has demonstrated efficacy in patients with paroxysmal/persistent AF and cardiovascular (CV) risk factors.
Mate Vamos, Anna Vagvolgyi, David S. McKindley, Stefan H. Hohnloser   +3 more
wiley   +1 more source

Comparison of HEMOlysis Markers Among Three Pulsed Field Ablation Systems: HEMO‐PFA Study

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background Pulsed field ablation (PFA) has emerged as a novel non‐thermal modality for atrial fibrillation (AF) ablation. While hemolysis is a known complication of PFA, comparative data among different systems remain limited. Methods We prospectively enrolled 150 consecutive AF patients undergoing ablation with one of three PFA systems ...
Kazuhisa Matsumoto, Kei Matsumoto, Naomichi Tanaka, Wataru Sasaki, Tsukasa Naganuma, Masataka Narita, Hitoshi Mori, Yoshifumi Ikeda, Takahide Arai, Shintaro Nakano, Kazuo Matsumoto, Ritsushi Kato   +11 more
wiley   +1 more source

Antiarrhythmic Drug Combination Therapy

Cardiac Electrophysiology Review, 1998
Enhanced antiarrhythmic ef~cacy may be achieved using a number of theoretic strategies. First, a drug that prolongs “time to ~rst recurrence” of a symptomatic arrhythmia could be combined with a second drug that changes the character of the recurrent arrhythmia from a hemodynamically compromising episode to one that produces few symptoms and no ...
openaire   +3 more sources

Tratamento de arritmias ventriculares malignas guiado por estudo electrofisiológico.

Acta Médica Portuguesa, 1998
The purpose of this study was to assess the results of the treatment of malignant ventricular tachyarrhythmias guided by electrophysiologic studies. Thirty patients with ventricular arrhythmias, aged 56.6 +/- 14.1 years, were submitted to EP testing. The
L Brandão, L Carpinteiro, J Sousa, M C Vagueiro   +3 more
doaj   +1 more source

Dominant Frequency Mapping as a Functional Tool for Substrate‐Guided Ventricular Tachycardia Ablation

Journal of Cardiovascular Electrophysiology, EarlyView.
Stimulus‐independent DF mapping integrates intracardiac signals with 3D anatomy to visualize high‐DF activity, with regions derived from SmartTouch and Pentaray catheters showing spatial correspondence with operator‐defined ablation sites. Quantitative analysis demonstrates higher proximity scores at ablation sites, low projection error, and good ...
Selim M. Zor, Wiert Hoeksema, Bart Baselmans, Michiel J. B. Kemme, Pieter G. Postema, Pranav Bhagirath   +5 more
wiley   +1 more source

Sodium-glucose transporter 2 inhibitors and their antiarrhythmic role: New insights and future perspective

Acta Marisiensis - Seria Medica
Sodium-glucose transporter 2 inhibitors have been identified as pleiotropic pharmacological agents with demonstrated efficacy in a wide range of pathologies.
Prația-Aron Diana-Ioana, Cozac Dan-Alexandru, Scridon Alina   +2 more
doaj   +1 more source

Rabbit models of heart disease. [PDF]

, 2008
Human heart disease is a major cause of death and disability. A variety of animal models of cardiac disease have been developed to better understand the etiology, cellular and molecular mechanisms of cardiac dysfunction and novel therapeutic strategies ...
Bers, Donald M, Pogwizd, Steven M
core  

Prospective Trial of Radiofrequency Catheter Ablation of High Dominant Frequencies After Pulmonary Vein Isolation in Non‐Paroxysmal Atrial Fibrillation (PAD‐AF Trial): A Multicenter, Randomized Clinical Trial

Journal of Cardiovascular Electrophysiology, EarlyView.
In persistent AF, adjunctive dominant frequency‐guided ablation after pulmonary vein isolation did not significantly improve outcomes. Limited overlap between high‐frequency sites and low‐voltage areas suggests functional–structural dissociation, while right atrial low‐voltage burden predicts recurrence.
Koji Kumagai, Tomoaki Hasegawa, Daisuke Kutsuzawa, Yuichi Hanaki, Masahide Harada, Hitoshi Hachiya, Yuhi Hasebe, Kazuki Noda, Minoru Yambe, Hirohito Metoki, Kazutaka Aonuma   +10 more
wiley   +1 more source

New possibilities of antiarrhythmic therapy of atrial fibrillation: A review

Терапевтический архив
Atrial fibrillation (AF) is the most common heart rhythm disorder. According to current recommendations, the treatment of AF includes 3 main directions: "A" – the appointment of anticoagulant therapy with an increased risk of thromboembolic complications,
Aida I. Tarzimanova, Alena Iu. Isaeva
doaj   +1 more source